Clinical Trial Detail

NCT ID NCT02017717
Title A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

glioblastoma multiforme

malignant glioma

Therapies

Nivolumab

Bevacizumab

Ipilimumab + Nivolumab

Age Groups: adult

No variant requirements are available.